Главная > Blogs > Feasibility of Alexander Cherkasky’s Inventions
Feasibility of Alexander Cherkasky’s Inventions29-09-2014, 23:31. Разместил: admin |
Feasibility of Alexander Cherkasky’s Inventions of Novel Antiautoimmune and Anticancer Fusion Proteins and Technologies for Fast, Simple and Inexpensive DNA and Complete Genome Sequencing Alexander Cherkasky Email: alexcherkasky@googlemail.com - I, Alexander Cherkasky, am award-winning and media-highlighted biologist (finished the Heinrich-Heine-University of Dusseldorf) and inventor of new causal therapies, cures for cancer, Alzheimer’s disease, autoimmune diseases such as multiple sclerosis and diabetes, new technologies for rapid, low-cost DNA sequencing (for personalized medicine, and preferable sequencing of genomes of marine organisms and useful plants), as well as I have inventions of new materials, diagnostic, test and control systems and lubricants. - I am owner of 8 German patents, I got them without a patent lawyer and have 4 US patent applications, 4 international patent applications and over 30 German patent applications. - In 1999 and 2000, as student at Goethe-Gymnasium in Dusseldorf, I partaked in scientific competition Jugend forscht “Youth researches” with theoretical problem solutions, i.e. inventions of cures for Alzheimer’s disease, autoimmune diseases and cancer. - Adjudicators of the “Youth researches” stated in 1999 and 2000 that I do not have results of clinical studies (it was a cynical requirement from a school student) and that I am still student at school, I shall do Abitur (finish school) and then make Vordiplom and Diplom (finish University). My status was considered also as reason for a denial of joint commercialization through joint company foundation or licensing. - The inventions I presented on “Youth researches” in 1999 and 2000 evoked interest of media and about me and inventions of mine reported known media including Stern (The Star), Bild der Wissenschaft (Picture of Science), Rheinische Post (Rhein Post), Westdeutsche Zeitung (Westgerman Newspaper), Neue Rhein Zeitung (New Rhein Newspapre) and other media. - In 2003 I partaked on the international competition of inventors IENA (Ideas-Inventions-New Products) in Nuremberg and won bronze medal and got the honorary certificate for my invention of novel anticancer fusion proteins. IENA is the largest international inventors competition in Germany already over 60 years. - You will find my economic proposals, including establishing the Inventions Implementation System for dynamic problem solutions on my blog: http://cherkaskysneweconomicmodel.blogspot.com/. This system shall proof and create solutions for problems of people and work independently from status of inventors and in addition to firms and academic and research organizations. These proposals concern all people, especially because everybody could need inventive, innovative biomedical help in order to heal, to treat a disease causally. - By doing searches (novelty searches for new inventions) I found, that several various inventions of mine were successfully experimentally implemented and confirmed, i.e. the feasibility and perspectives of my inventions, (i.e. inventions for which I have clearly documented priority) especially of cures for autoimmune diseases and cancer and inventions for fast, simple and inexpensive DNA sequencing, were clearly demonstrated by other scientists. 1. The German and American company Micromet (NASDAQ: MITI), which was sold to Amgen, has experimentally confirmed my prior inventions of anticancer fusion proteins and my invention of the fusion proteins against autoimmune diseases (so called Fc-Autoantigen Fusion Proteins (against multiple sclerosis and diabetes), e.g. Fc-AchR against Myasthenia gravis). Micromet ignored my published comments on Google Finance, in Discussion Group about Micromet. Please see the following links: http://finance.google.com/group/google.finance.14184091/browse_thread/thread/35a66fe3177f6d4c?hl=en# http://finance.google.com/group/google.finance.14184091/browse_thread/thread/7cc3d09823db06a7?hl=en# http://alexandercherkasky.blogspot.com/ Micromet got income through selling stocks and licenses. Micromet’s issued by error of examiner Mertz US patent US7323440 (each US patent issued by error of examiner can be invalidated/rejected after reconsideration or reexamination of the United States Patent and Trademark Office (USPTO)) (Filed: February 12, 2003, filed in the US: May 23, 2005 (after publication of my DE10160248 in 2003), claiming foreign priority of February 13, 2002, US patent issued: January 29, 2008) is not new because of my prior DE10160248 (Filed: December 07, 2001 and published on July 26, 2003). The antiautoimmune cure formula Fc-Autoantigen, e.g. Fc-AchR is identical in my prior document DE10160248 and in Micromet’s US7323440. In example 20 of US7323440 is stated “Inventive, Illustrative Fusion Protein AchR-Fc”, examples 19-24 concern feasibility of AchR-Fc and about feasibility is stated in example 24: “Antibody titers against AchR were significantly reduced in those groups of animals treated with the recombinant AchR-Fc protein suggesting a depletion of autoreactive B cells directed against AchR.” My inventions of antiautoimmune proteins with the general formula Fc-Autoantigen, covered in my prior DE10160248, which Micromet wanted to steal in his issued by error of examiner Prema Mertz US patent 7323440 include: 1. Fc-AchR against Myasthenia gravis, 2. Fc-MBP against Multiple Sclerosis, 3. Fc-GAD against Diabetes mellitus, 4. Fc-insulin receptor against Diabetes mellitus, 5. Fc-an elected histone protein against SLE (Systemic Lupus Erythemathosus), 6. Fc-an elected ribonucleoprotein against SLE, 7. Fc-DNA-binding domain (DBD) complexed with DNA against SLE, 8. Fc-RNA-binding domain (RBD) complexed with RNA against SLE, 9. Fc-DBD (DNA-binding domain) against SLE, 10. Fc-RBD (RNA-binding domain) against SLE, 11. Fc-TSHR against Basedow disease, 12. Fc-Desmoglein 1 against Pemphigus foliaceus (autoimmune skin disease), 13. Fc-Desmoglein 3 against Pemphigus vulgaris (autoimmune skin disease), 14. Fc-BP 180 against Bullous Pemphigoid (autoimmune skin disease), 15. Fc-collagen-Type-7 against Epidermolysis bullosa aquesita (autoimmune skin disease), 16. Fc-non-collagenous domain of basal membrane collagen-type 4 against Goodpasture syndrome, 17. Fc-HSP against rheumatoid arthritis, 18. Fc-Integrin gpIIb:IIIa against autoimmune thrombopenia, 19. Fc-a Rhesus antigen against hemolylic anemia, and 20. Fc-I-Antigen against hemolytic anemia. The anticancer (antileukemia) drug candidate “Blinatomumab” of Micromet covered by US7635472, US7235641, US20070249529, US20090291072 and US20090022738 is not inventive because of my prior DE10162870 (Filed: December 20, 2001), DE19925052 (Filed: June 01, 1999), DE10161899 (Filed: December 17, 2001) and DE10161738 (Filed: December 15, 2001) covering anticancer fusion proteins. The novel (single chain) fusion proteins covered by my DE10162870 “Fusion Proteins against B Cell Tumors” bind both T cells and (preferably) B cells (or other cells) and direct T cells against B cells (or other cells). This my patent application DE10162870 was rejected by examiner Christa Pitsch-Machacek (German Patent and Trademark Office, Deutsches Patent- und Markenamt, DPMA), and this examiner Pitsch-Machacek was also examiner for Micromet and its research director Patrick Baeuerle. Dr. Pitsch-Machacek considered German patent applications DE60203324, DE69911793, DE69909459 and DE69233068 of Micromet and DE4311835 of Patrick Baeuerle. Also my German patent application DE10160248 covering fusion proteins with formula Fc-Autoantigen against autoimmune diseases was also rejected by examiner Pitsch-Machacek. This Pitsch-Machacek rejection of my DE10162870 covering anticancer fusion proteins and DE10160248 (covering my antiautoimmune fusion proteins) helped Micromet to commercialize my anticancer and antiantoimmune inventions, i.e. inventions I have clearly documented priority. Paradoxingly, the current President of the German Patent and Trademark Office Rudloff-Schäffer stated, that she investigated this case and trust Pitsch-Machacek whereby Pitsch-Machacek assured Rudloff-Schäffer, that Pitsch-Machacek does not know Micromet. If Rudloff-Schäffer would really investigate this case, she would find, that Pitsch-Machacek was examiner for Micromet and Baeuerle. 2. The American company Halcyon Molecular (mentioned in the article of Eric Schadt (Nr. 43), in the list of references in the article “DNA Sequencing” in Wikipedia) is based on my German patent DE19937512 for fast genome sequencing and this my patent was cited in the key US patent US8153438 (my patent was cited in references as foreign patent document and in other references) of Halcyon Molecular, but this company does not have priority, and this US patent of Halcyon Molecular is not new and not inventive. Halcyon Molecular did referenced my German patent DE19937512, but did not explained the difference between my patent DE19937512 and their issued by error of examiner patent US8153438 that would make the patent of Halcyon Molecular new and inventive. In this US patent US8153438 is stated, that Richard Feynman dreamed in 1959 about direct researching DNA by using electron microscopy. 20 years later, in 1979 F.P. Ottensmeyer stated that an easy and accurate reading from a single molecule was not possible, because of the uncontrollable placing of DNA. And also 20 years later, in 1999 I proposed the optimal solution in my patent DE19937512. In this patent DE19937512 I proposed the combination of controllable placing, stretching (extending, aligning, elongating, straightening) DNA (whereby stretching DNA is combined with DNA immobilization) and sequencing by electron microscopy. Please see the link to the issued by error of examiner US patent US8153438 of Halcyon Molecular: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8153438.PN.&OS=PN/8153438&RS=PN/8153438 My German patent DE19937512 (also Fig. 6) is also the basis for non-destructive sequencing by tip microscopy (including multiple tip or multiple edge nano-knife edge probes, (multiple nano-knife edge microscopy)) and electron microscopy developed by American firms Reveo (Dr. Sadeg Faris) and ZS Genetics. Michael Metzger stated in his review “Sequencing technologies – the next generation” (Nature Reviews Genetics 11, 31-46 (January 2010): “Demand has never been greater for revolutionary technologies that deliver fast, inexpensive and accurate genome information.” Also American inventor R. Bension mentioned me and my German patent DE19937512 for fast genome sequencing in his US patent US7163658. This his US patent was basis for his research published in Small (B.A.Ashcroft et al “An AFM/Rotaxane Molecular Reading Head for Sequence-Dependent DNA Structures” Small 2008, 4, No. 9, 1468-1475). William Roy III Glover (ZS Genetics Inc.) (in his US patent application US20060029957 “Systems and methods of analyzing nucleic acid polymers and related components”, filed: July 14, 2005 and claiming priority of July 14, 2004 as well as in his issued by error of examiners US patents US7604942, US7604943, US7291468, US7291467, US7288379 and US patent applications US20100105055, US20080227095, US20080199871, US20070190557, US20070134699, US20060024717 and US20060024718) discloses sequencing by electron microscopy. My prior German patent DE19937512 “Method and device for rapid genome sequencing by stretching/straightening DNA” (Filed: August 09, 1999, published as patent application: February 15, 2001 and published as patent: August 24, 2006) describes fixing of DNA sequence(s) to substrate, stretching/straightening DNA (including DNA immobilization) and sequencing by microscopy, especially electron microscopy or other physical, optical methods (for example 0018 and claim 1 of the patent DE19937512). Because of this my patent DE19937512, US patent applications of Nagayama US20020086317 and US20070038261 are not inventive. Ying-Ja Chen, Eric E. Roller and Xiaohua Huang (in their article „DNA sequencing by denaturation: experimental proof of concept with an integrated fluidic device”, Lab Chip, 2010, 10, 1153 D0I:10.1039/b921417h, (published online 2010 February 9) and published in final edited form as: Lap Chip. 2010 May 7; 10(9): 1153-1159) confirmed feasibility of my invention of rapid, simple and low-cost/inexpensive DNA sequencing by denaturation. My German patent DE102008037890 “Method and Device for Sequence Analysis of Nucleic Acids” (Filed: August 15, 2008, published: April 08, 2010) discloses the invention of DNA sequencing by denaturation/unwinding (claim 1b) and detection by using optical methods including spectral analysis and microscopy (claim 1c). Denaturation occurs through heating or denaturating substances (claim 6c and 6e). Sequencing by denaturation and renaturation is also disclosed in claim 3. The combination of denaturation of double-stranded DNA preferably by heating and sequencing by using optical methods including microscopy was also disclosed in the claims 1, 2 and 9 of my German patent application DE19937512 A1 for fast genome sequencing. Kyohei Terao, Masao Washizu and Hidehiro Oana (in their article “On-site manipulation of single chromosomal DNA molecules by using optically driven microstructures”, first published in Lab on a Chip as an advance article on the web 23 rd June 2008, (Lab Chip, 2008, 8, 1280-1284)) described controlled DNA winding around one bobbin or two bobbins and confirmed feasibility of my invention. My prior German patent DE19929530 “Method and device for fast genome sequencing” (filed: June 28, 1999, published as patent application: January 04, 2001 and published as patent: May 24, 2006) discloses the picking up DNA and controlled (controllable) DNA winding around the bobbin or bobbins (for example claim 1 of my patent DE19929530). Please see my blog http://alexandercherkasky.blogspot.com/. 3. The Nobel Laureate Joshua Lederberg (please see the blog: http://alexandercherkasky.blogspot.com/) (in his US20040033584 “Therapeutic use of particles displaying pathogen-specific moiety” (claiming priority of December 21, 2002, i.e. after publication of my prior DE19818938 on November 04, 1999) and the company Vector Logics (David Curiel in WO2006119449, Filed: May 04, 2005) confirmed my anticancer invention of genetically modified anticancer viruses with antibodies or receptors for recognizing cancer cells, which was described in my prior patent application DE19818938 (filed in 1998). 4. The confirmation of my anticancer fusion proteins (described in my prior DE19925052, DE10162870, DE10161899 and DE10161738) done by Anke Kretz-Rommel (in WO2007048022, filed: October 21, 2005) at the US firm Alexion is described on my blog: http://cherkaskyoffers.blogspot.com/. Thus the inventions I propose (and proposed as school student) are implemented and confirmed (the feasibility was clearly demonstrated). I have 4 US patent applications (US20090070900, US20080242565, US20080200652 and US20070106066) covering new fusion proteins against cancer and inflammations and for fast diagnosis of various diseases as well as covering new materials, labels and new lubricants. Google proposed search for Novel Cherkasky fusion proteins (by entering my name in Google search) and Google published my US patent application US20080200652 for Novel Cherkasky antibody-binding proteins (which are blockbusters in biotechnology, because these my fusion proteins can be used both for therapy and diagnosis and can enhance, boost therapeutic effects of available antibodies) on Google patents and other my US patent applications on the Google service Patent Alert. Please see the following links: http://www.google.com/patents/US20080200652 http://www.google.de/search?q=cherkasky++patent+alert&btnG=Suche&hl=de&gbv=2&spell=1&ct=broad-revision&cd=1 http://www.google.com/custom?domains=www.patentalert.com&q=cherkasky&sa=Google+Search&sitesearch=www.patentalert.com&client=pub-6190068236505244&forid=1&ie=UTF-8&oe=UTF-8&cof=GALT%3A%23008000%3BGL%3A1%3BDIV%3A%23336699%3BVLC%3A663399%3BAH%3Acenter%3BBGC%3AFFFFFF%3BLBGC%3A336699%3BALC%3A0000FF%3BLC%3A0000FF%3BT%3A000000%3BGFNT%3A0000FF%3BGIMP%3A0000FF%3BFORID%3A1%3B&hl=en My German patent documents were basis for other scientists who referenced/cited these my patent documents in their US patents (US7902156 and US7557182 cited my DE19953696 covering cures for Alzheimer’s disease, other neurological diseases and cancer, US 7999073 cited my German patent DE19925052 covering novel pharmaceutical preparations especially for use in gene therapy, US8034766 referenced my DE19822406 (presented by “Youth researches” in 1999 and highlighted by Stern (The Star)) against prions and for prion decontamination (the Assignees for the US patent US8034766 for prion decontamination are E I du Pont de Nemours and Company and University College London) and as mentioned above, the US patents US8153438 and US7163658 referenced my German patent DE19937512 for fast DNA sequencing, whereby the US patent US8153438 of Halcyon Molecular for fast sequencing is not new and not inventive because of my German patent DE19937512). My patent application DE19822406 (filed: May 12, 1998 and published: November 25,1999) covers protease-(containing) fusion proteins for specific elimination (selective proteolysis) of pathogenic proteins such as prions, amyloid proteins, oncoproteins, immune complexes and other dangerous proteins. It means that my DE19822406 discloses cures for nephritis (glomerulonephritis), arthritis, uvetitis, vasculitis, other immune complex and autoimmune and inflammatory diseases, prion diseases, cancer and Alzheimer’s disease. Alexander Cherkasky Email: alexcherkasky@googlemail.com Вернуться назад |